InvestorsHub Logo
Followers 144
Posts 27707
Boards Moderated 3
Alias Born 02/07/2004

Re: None

Wednesday, 01/26/2022 1:26:44 AM

Wednesday, January 26, 2022 1:26:44 AM

Post# of 367
MediWound Ltd (MDWD) Reports Positive Ph2 EscharEx Data - Wells Fargo
Article


January 25, 2022 8:42 AM EST

https://www.streetinsider.com/Analyst+Comments/MediWound+Ltd+%28MDWD%29+Reports+Positive+Ph2+EscharEx+Data+-+Wells+Fargo/19499259.html

Wells Fargo analyst Jacob Hughes reiterated an Overweight rating and $7.00 price target on MediWound Ltd (NASDAQ: MDWD) after the company reported positive top-line results from its USPh2 adaptive design study of EscharEx for the debridement of venous leg ulcers (VLUs).

The analyst stated "We reiterate our Overweight rating and continue to believe the market is undervaluing MDWD's pipeline. While the sentiment in sector is clearly a near-term headwind, overtime, we expect MDWD's valuation to improve as it executes on NexoBrid and EscharEx's potential."

For an analyst ratings summary and ratings history on MediWound Ltd click here. For more ratings news on MediWound Ltd click here.

Shares of MediWound Ltd closed at $2.51 yesterday.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent MDWD News